Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIUMPH: recindos trastuzumab with or without adebrelimab as first-line therapy for HER2-altered advanced biliary tract cancer
ChiCTR2600136023Phase 2Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Nov 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab and adebrelimab in biliary cancer (2 arms), sponsored by First Hospital of China Medical University. Primary endpoint: Objective response rate. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
trastuzumabadebrelimab
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2600136023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600136023.